Retatrutide is a once-weekly injectable medication developed by Eli Lilly that has shown promise in the treatment of obesity and type 2 diabetes
The results showed that the expression of positive marker proteins in defatted milk sEVs was higher than that in whole milk derived sEVs (Figure 1D and Figure S1)
However, when these findings were tested under conditions that simulate the natural process of lipid digestion in the gastrointestinal tract, using a method known as the potential of Hydrogen (pH)-stat test, the expected inhibitory effects were not observed
In a comparative study for type 2 diabetes, semaglutide lowered A1C levels by about 1% to 2%, while tirzepatide lowered A1C by 2% to 2.5%.In a head-to-head comparative study looking at weight loss, average weight loss was 50.3 lbs (22.9 kg) with tirzepatide compared to 33.1 lbs with semaglutide Weight loss with tirzepatide may be superior to semaglutide, but this can vary among patients
Pancreatitis : Semaglutide may increase the risk of pancreatitis
Clinical trials showed that approximately 2539% of people experience nausea at some point during semaglutide therapy, with most cases rated as mild to moderate
